A phase II study of mitomycin C, cisplatin and continuous infusion 5-fluorouracil (MCF) in the treatment of patients with carcinoma of unknown primary site

Carcinoma of unknown primary site remains a common clinical diagnosis, accounting for between 5 and 10% of all cancer patients. Numerous combination chemotherapy regimens have been used in the management of carcinoma of unknown primary site, resulting in response rates of 0–48%. We present the resul...

Descripción completa

Detalles Bibliográficos
Autores principales: Macdonald, A G, Nicolson, M C, Samuel, L M, Hutcheon, A W, Ahmed, F Y
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2002
Materias:
Clinical
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2375343/
https://www.ncbi.nlm.nih.gov/pubmed/11953879
http://dx.doi.org/10.1038/sj.bjc.6600258

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2375343/
https://www.ncbi.nlm.nih.gov/pubmed/11953879
http://dx.doi.org/10.1038/sj.bjc.6600258

Ejemplares similares